You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亞盛醫藥-B(06855.HK)擬先舊後新配售最多2650萬股 總籌11.7億港元
格隆匯 02-04 06:53

格隆匯 2 月 4日丨亞盛醫藥-B(06855.HK)發佈公吿,2021年2月3日,公司、賣方與配售代理(即摩根大通及中金公司)訂立配售及認購協議,據此,配售代理將盡其所能促使承配人按配售價每股銷售股份44.20港元購買最多2650萬股銷售股份;及公司已同意根據一般授權按認購價每股44.20港元(即相等於配售價)向賣方發行最多2650萬股新認購股份。

銷售股份最高數目相當於公司現有已發行股本約11.71%及緊隨認購事項交割後公司經擴大已發行股本約10.49%(假設公司已發行股本自本公吿日期至認購事項交割將不會有任何變動,惟公司發行認購股份除外)。

預期認購事項將予籌集的所得款項總額將約為11.713億港元及估計認購事項產生的所得款項淨額將約為11.5364億港元。董事認為,配售事項及認購事項將進一步鞏固集團的財務狀況,併為集團提供額外營運資金。其中,認購事項的所得款項淨額約50%將用於關鍵候選產品APG-2575的臨牀試驗;約20%將用於支持核心產品HQP1351全面批准的註冊性試驗及商業化;約20%將用於其他分子及臨牀前資產的臨牀研發;及約10%將用一般公司用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account